Course Opens
06/26/2025
Credits
0.5
Credit Expires
07/01/2026
Antibody-drug conjugates (ADCs) have recently been approved to treat HER2-negative metastatic breast cancer (MBC). In an ADC, a cytotoxic chemotherapeutic agent is conjugated to a monoclonal antibody directed against a tumor-associated antigen. Conjugation fundamentally alters tissue accumulation and pharmacodynamics of the therapeutic agent, and leads to substantial alterations in efficacy and adverse effects. Ensuring that clinicians comprehend the limits of chemotherapy and understand the structure, targets, payloads, and mechanisms of action (MOAs) of ADCs can lead to improved quality of life and outcomes for patients with HER2-negative MBC.
In the first of this 3-part CEC Oncology BriefCase series, expert faculty introduce clinicians to ADC therapy for HER2-negative MBC and hear from a patient advocate about patient concerns regarding this new therapy option.
At the conclusion of this activity, learners will be able to better:
This program has been supported by an independent educational grant from Gilead Sciences, Inc.
Academic and community oncologists, nurse practitioners (NPs), physician associates (PAs), nurses and pharmacists
In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Creative Educational Concepts, LLC, designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 0.50 contact hours (0.05 CEUs) of continuing pharmacy credit (JA0007101-0000-25-006-H01-P).
This activity is designated for 0.50 contact hours.
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.
This activity is designated for 0.50 contact hours.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:
OCN®
Treatment
CBCN®
Treatment
CPHON®
Treatment
AOCNP®
Treatment
This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education Credit for learning and change.
Creative Educational Concepts, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until 07/01/2026. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CE Concepts is based in Radnor, Pennsylvania, USA. Please retain your certificate as proof of completion.
It is the policy of CE Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CE Concepts, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Nanda reports the following financial relationships:
Advisory Board: Arvinas; AstraZeneca; Daiichi-Sankyo; Exact Sciences Corporation; GE Pharmaceuticals; Gilead Sciences, Inc.; Guardant Health; Lilly; Merck & Co., Inc.; Moderna, Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma; Pfizer Inc.; Sanofi; Seagen Inc.; Stemline Therapeutics, Inc.; and Summit Therapeutics Inc.
Research Support: Arvinas; AstraZeneca; Bristol Myers Squibb Company; Corcept Therapeutics; Genentech, Inc./Roche; Gilead Sciences, Inc.; GSK; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma; Pfizer Inc.; Relay Therapeutics; Seattle Genetics, Inc.; Sun Pharma; and Taiho Oncology, Inc.
Dr. Roman reports the following financial relationships:
Advisory Board: Astellas Pharma US, Inc.; Daiichi-Sankyo; and Genentech, Inc.
Ms. Anderson-Benjamin reports no financial relationships to disclose.
The following individuals have no financial relationships to disclose:
Alaa Bawaneh, MD, PhD (Peer Reviewer)
Joshua Caballero, PharmD, BCPP, FCCP (Peer reviewer)
Nichole Lainhart (Planning Committee)
David Modrak, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
*All identified conflicts of interest have been mitigated.
Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CE Concepts, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Post-tests, credit request forms, and activity evaluations must be completed online
(requires free account activation), and participants can print their certificate or statement of
credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.
Visit the Creative Educational Concepts Privacy Policy page for complete information about our privacy policy and practices.
Call us at 859-260-1717 • info@ceconcepts.com
BC-133-070125-47
Call us at 859-260-1717 • info@ceconcepts.com
